Leerink Partners Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $110

Leerink Partners analyst Faisal Khurshid has maintained an 'Outperform' rating on Protagonist Therapeutics (NASDAQ: PTGX) and raised the price target from $107 to $110.